但对实验的描述是严谨的。同种类型的神经连接可以再生，不同类型的神经连接应该不能存活。看这人的背景大致可以知道这位为什么挺X。这位应该是相信了X在中国人身上试验的数据。就X对神经解剖的知识，和对实验工作的严谨性方面（973项目的文章可见一斑，完全是弄虚作假凑数据），还不说细胞和分子水平的，估计肖在美国是混不下去的。如果能混出来名堂，并且一路看好，也不会回国。

Kenneth M. Peters, M.D., chairman
Urology department
Beaumont Hospital, Royal Oak, Mich.
Dr. Peters became chairman of the department of Urology at Beaumont Hospital in
Royal Oak in 2007.
He joined Beaumont in 1991 as a urology resident, and completed an additional urology
fellowship at the hospital after his residency.
Widely recognized as a leader in conducting research, Dr. Peters is internationally
known for his work on nerve rerouting surgery, interstitial cystitis and neuromodulation.
He has written numerous peer-reviewed journal articles and book chapters on
incontinence, interstitial cystitis and neuromodulation. He has twice won the Society for
Urodynamics and Female Urology clinical research award. Dr. Peters has research
grants from the National Institutes for Health and Industry, and he is a grant reviewer for
the National Institutes of Health.
He received his medical degree from Case Western Reserve University School of
Medicine. He is an active and well-respected resident educator. He is a member of the
American Urological Association, Michigan Urological Society, the Society for
Urodynamics and Female Urology, International Continence Society and International
Society for Pelvic Neuromodulation. He was recently voted by the American Urological
Association to serve on its research council.
Dr. Peters has a private practice in Royal Oak, Mich. and lives in Huntington Woods.

一篇文章的摘要：

Keywords:

* cystitis;
* interstitial;
* LUTS;
* overactive;
* neuromodulation;
* urinary bladder

Abstract
Aims

Chronic pudendal nerve stimulation (CPNS) is a logical alternative particularly in those who fail sacral stimulation. We evaluated symptoms, complications, and satisfaction after CPNS.
Methods

We retrospectively reviewed patients having a tined lead placed at the pudendal nerve via the ischial-rectal approach. Demographics, history, complications, and pre-implant voiding diary data were collected. In those responding to CPNS, post-implant symptom changes were measured with the Interstitial Cystitis Symptom and Problem indices (ICSI-PI) and voiding diaries at 3, 6, and 12 months, and a mailed survey.
Results

The majority of 84 patients (78.6% female; age 51.8&#8201;±&#8201;16.9 years) had interstitial cystitis/painful bladder syndrome, or overactive bladder. Pudendal response (≥&#8201;50% improvement) occurred in 60/84 (71.4%), however 5 of these chose sacral neuromodulation. Almost all (93.2%) who had previously failed sacral neuromodulation responded to pudendal stimulation. Outcomes were evaluated in 55 continuing on CPNS (median follow up 24.1 months). Seven complications requiring 5 revisions, and 4 other re-operations occurred. Five were explanted. Over time, significant improvements in frequency (P&#8201;<&#8201;0.0001), voided volume (P&#8201;<&#8201;0.0001), incontinence (P&#8201;<&#8201;0.0001), and urgency (P&#8201;=&#8201;0.0019) occurred. ICSI-PI scores significantly improved over 12 months (P&#8201; <&#8201;0.0001). Survey responses indicated that most still had a device (35/40; 87.5%) continuously in use (24/29; 82.8%), and overall bladder, pelvic pain, incontinence, urgency, and frequency symptoms had improved.
Conclusions

CPNS is a reasonable alternative in complex patients refractory to other therapies including sacral neuromodulation. Continued research is needed to fully assess long-term outcomes and identify predictors of success. Neurourol. Urodynam. 29:1267–1271, 2010. &#169; 2009 Wiley-Liss, Inc.